Insilico Medicine nominates pan-TEAD inhibitor as a potential solution for drug resistance in solid tumor patients

Insilico Medicine, a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM6331, a potential best-in-class pan-TEAD inhibitor, as a preclinical candidate compound (PCC) generated by Chemistry42, its proprietary generative chemistry-driven molecule design engine, targeting the Hippo pathway for the treatment of advanced solid tumors.